Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
September, 2026
September 2026
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Mohamed El Belghiti Alaoui: The Promise of AAV Gene Therapy in Hemophilia A
AI generated
Aug 3, 2026, 13:03

Mohamed El Belghiti Alaoui: The Promise of AAV Gene Therapy in Hemophilia A

Mohamed El Belghiti Alaoui, Independent Researcher, shared a post on LinkedIn:

“AAV Gene Therapy (Factor VIII) for Hemophilia A.

Consider that a cure for the once‑incurable bleeding disorder Hemophilia A is now in clinical trials, offering hope beyond lifelong infusions.

We are shifting from merely managing bleeding episodes to rewriting patients’ biology, enabling their own cells to produce factor VIII continuously.

  • Standard Hemophilia A care requires frequent factor VIII infusions, causing inhibitor formation, venous access challenges, and prohibitive costs.
  • AAV vector delivers functional F8 gene to hepatocytes, enabling continuous endogenous factor VIII production and durable hemostasis.
  • Approval would provide a one‑time infusion, eliminating lifelong prophylaxis and dramatically improving patient quality of life.

Would you trust this one‑time gene therapy for yourself or a loved one?”

Mohamed El Belghiti Alaoui: The Promise of AAV Gene Therapy in Hemophilia A

Stay updated with Hemostasis Today.

AAV Gene Therapy Factor VIII Health Hematology Hemophilia A Hemostasis Hemostasis News Hemostasis Today Medicine Mohamed El Belghiti Alaoui
NewsFeed